Bioventus Inc.

NasdaqGS BVS

Bioventus Inc. EBITDA for the Trailing 12 Months (TTM) ending September 28, 2024: USD 32.28 M

Bioventus Inc. EBITDA is USD 32.28 M for the Trailing 12 Months (TTM) ending September 28, 2024, a 153.04% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Bioventus Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -60.86 M, a 41.77% change year over year.
  • Bioventus Inc. EBITDA for the Trailing 12 Months (TTM) ending October 01, 2022 was USD -104.53 M, a -288.16% change year over year.
  • Bioventus Inc. EBITDA for the Trailing 12 Months (TTM) ending October 02, 2021 was USD 55.55 M, a -4.73% change year over year.
  • Bioventus Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 58.31 M.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
NasdaqGS: BVS

Bioventus Inc.

CEO Mr. Robert E. Claypoole
IPO Date Feb. 11, 2021
Location United States
Headquarters 4721 Emperor Boulevard
Employees 1,030
Sector Health Care
Industries
Description

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Similar companies

VVOS

Vivos Therapeutics, Inc.

USD 5.06

4.33%

BJDX

Bluejay Diagnostics, Inc.

USD 3.36

-7.95%

NUWE

Nuwellis, Inc.

USD 1.05

3.96%

HSCS

Heart Test Laboratories, Inc.

USD 3.26

1.24%

StockViz Staff

January 15, 2025

Any question? Send us an email